Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2015
At a glance
- Drugs Erlotinib (Primary) ; Sorafenib (Primary)
- Indications Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 29 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Mar 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Nov 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.